MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma
The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
Loss of membrane MHC class I protein expression in most of tumor cells in advanced melanomas predicts primary resistance to anti–CTLA-4, but not anti-PD1, treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In another study, MHC I downregulation via transcriptional repression was associated with primary resistance to anti-CTLA-4 therapy but not to anti-PD-1 therapy, and the response to anti-PD-1 was more dependent on MHC II expression linked to an IFN-γ-regulated module of genes (97).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [97]
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895
HTSeq—a Python framework to work with high-throughput sequencing data
Anders, S., Pyl, P. T., & Huber, W. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btu638 · Cited by 21,464
GSVA: gene set variation analysis for microarray and RNA-Seq data
Hänzelmann, S., Castelo, R., & Guinney, J. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-7 · Cited by 15,440
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationSalmon provides fast and bias-aware quantification of transcript expression
Patro, R., Duggal, G., Love, M. I., Irizarry, R. A., & Kingsford, C. (2017) · Nature Methods · doi:10.1038/nmeth.4197 · Cited by 12,700
Cingolani, P., Platts, A., Wang, L. L., Coon, M., Nguyen, T., Wang, L., Land, S. J., Lu, X., & Ruden, D. M. (2012) · Fly · doi:10.4161/fly.19695 · Cited by 11,816
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Cited by
Items 601–623 of 623
Cao, J., Tu, D.-Y., Zhou, J., Jiang, G.-Q., Jin, S.-J., Su, B.-B., Tang, H., Tang, Y.-H., Wang, A.-Q., Wang, Q., et al. (2022) · doi:10.3389/fimmu.2022.997265.s002
Yamada, R., Kai, K., Hidaka, K., Yoshii, D., Shirotani, R., Takahashi, T. A., Miyasato, Y., Murakami, S., Mikami, Y., Komohara, Y., et al. (2026) · Surgical Case Reports · doi:10.70352/scrj.cr.26-0071
Iorgulescu, J. B., Ruthen, N., Ahn, R., Panagioti, E., Gokhale, P. C., Neagu, M., Speranza, M. C., Eschle, B. K., Soroko, K. M., Piranlioglu, R., et al. (2023) · doi:10.3389/fimmu.2023.1297932.s001
Lynce, F. C., Stevens, L. E., Li, Z., Brock, J. E., Gulvady, A. C., Huang, Y., Nakhlis, F., Patel, A., Force, J. M., Haddad, T. C., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25123842
Lynce, F. C., Stevens, L. E., Li, Z., Brock, J. E., Gulvady, A. C., Huang, Y., Nakhlis, F., Patel, A., Force, J. M., Haddad, T. C., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25124070
Prioritization of VSV-based OV to overcome ICI-resistant melanomas.
Long, B. R. (2023) · eScholarship@McGill (McGill) · doi:10.82308/2424
癌の抗原提示とホストの抗癌免疫におけるNLRC5発現の役割の研究
Sun, X. (2024) · Institutional Repositories DataBase (IRDB) · doi:10.14943/doctoral.k15898
INIBIDORES DE PONTOS DE VERIFICAÇÃO IMUNE UTILIZADOS NO TRATAMENTO DO CÂNCER
Errante, P. R. (2023) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Cellular Localization Of Inflammatory Signaling As A Determinant Of Tumor-Immune Biology
Johnson, L. (2001) · Scholarly Commons (University of Pennsylvania)
Agent-based Modeling of Immunological Synapse Dynamics
Siokis, A. (2019) · Digitale Bibliothek Braunschweig (Verbundzentrale Göttingen (VZG)) · doi:10.24355/dbbs.084-201909111204-0
Les facteurs prédictifs de réponse aux inhibiteurs de points de conrtôle immunitaires
Moneyron, C. (2020) · HAL
Editorial: Advances in mathematical and computational oncology, volume III
Bebis, G. N., Kato, M., Kohandel, M., Wilkie, K. P., Antunes, D. A., Chen, K., & Dou, J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1282882
MHC class IIタンパク質発現を制御するユビキチンリガーゼの機能解析
井上, 綾. (2023) · Institutional Repositories DataBase (IRDB) · doi:10.14943/doctoral.k15431
Talab, T. A. E.-H., Elgendy, W., & Mashad, S. M. E. (2025) · Egyptian Journal of Pathology · doi:10.4103/egjp.egjp_26_25
Lozano, C. C., Vazquez, E. N., Kolev, A., Honan, A. M., El-Rifai, W. M., Zaika, A., & Chen, Z. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.01.715843
Shteinman, E. R., Attrill, G. H., Palendira, U., Scolyer, R. A., Long, G. V., Wilmott, J. S., & Vergara, I. A. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08820-9
Immune-cell depleted diffuse large B-cell lymphomas have reduced expression of MHC class IPreprint
Huse, K., Blaker, Y. N., Wise, J., Enemark, M. H., Arffman, M., Sharma, A., Meriranta, L., Nakken, S., Isaksen, K. T., Spasevska, I., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.01.748487
Ray, R. R., Polin, L., Geng, R., Kidder, B., & Jacob, J. B. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.12.758076
PD-L1 testing in cutaneous malignancies: interpretation, clinical utility, and unresolved challenges
Samman, A. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-026-04605-0
Wang, J., Wu, Z., Zheng, M., Yu, S., and, X. Z., & Xu, X. (2022) · doi:10.3389/fgene.2022.1025306.s001
Lanuza, P. M., Alonso, M. H., Hidalgo, S., Uranga-Murillo, I., García-Mulero, S., Arnau, R., Santos, C., Sanjuan, X., Santiago, L., Comas, L., et al. (2022) · doi:10.3389/fimmu.2022.890836.s003
Metadata
- Authors
- Rodig, S. J., Gusenleitner, D., Jackson, D. G., Gjini, E., Giobbie-Hurder, A., Jin, C., Chang, H., Lovitch, S. B., Horak, C., Weber, J. S., Weirather, J. L., Wolchok, J. D., Postow, M. A., Pavlick, A. C., Chesney, J., & Hodi, F. S.
- Affiliations
- Brigham and Women's Hospital (US)
- Dana-Farber Cancer Institute (US)
- Bristol-Myers Squibb (United States) (US)
- Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
- NYU Langone Health (US)
- Memorial Sloan Kettering Cancer Center (US)
- University of Louisville (US)
- Corresponding author
- Rodig, Scott J.
- Hodi, F. Stephen
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2018-07-18
- Volume
- 10
- Issue
- 450
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2883970691
- Cited by
- 579
- References
- 59
- Citations by year
- 2026: 38 · 2025: 48 · 2024: 75 · 2023: 101 · 2022: 94 · 2021: 79 · 2020: 76 · 2019: 55 · 2018: 12
- FWCI
- 20.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Funded by Bristol-Myers Squibb (N/A)
- NIH/NCI Cancer Center (P30 CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- metastatic melanoma, MHC class I expression, MHC class II expression, CTLA-4 blockade, anti-PD-1 therapy, immune checkpoint inhibitors, interferon-gamma, innate immunity, tumor antigen presentation, antitumor immunity, predictive biomarkers
- MeSH terms
- HLA Antigens, Humans, Immunity, Innate, Immunotherapy, Melanoma, Transcription, Genetic, Gene Expression Regulation, Neoplastic, CTLA-4 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.